Review of erlotinib in the treatment of advanced non-small cell lung cancer
暂无分享,去创建一个
[1] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Rossi,et al. Erlotinib in non-small-cell lung cancer , 2007, Expert opinion on pharmacotherapy.
[3] U. Gatzemeier,et al. Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC) , 2007 .
[4] L. Beckett,et al. Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism , 2007 .
[5] J. Jett,et al. Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer , 2007 .
[6] C. Obasaju,et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: Updated report with survival , 2007 .
[7] Petr Zatloukal,et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 , 2007 .
[8] O. Spleiss,et al. Association between different potential predictive markers from TRUST, a trial of erlotinib in non-small cell lung cancer (NSCLC) , 2007 .
[9] C. Rudin,et al. A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer , 2007 .
[10] M. Krzakowski,et al. Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study , 2007 .
[11] P. Novotny,et al. Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB) , 2007 .
[12] P. Hainaut,et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. , 2007, Cancer research.
[13] R. Gray,et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. , 2007, Journal of the National Cancer Institute.
[14] P. Jänne,et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Marshall W. Anderson,et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. , 2007, Cancer research.
[16] J. Milanowski,et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Sapino,et al. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens , 2007, Molecular Cancer Therapeutics.
[18] M. Meyerson,et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Park,et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. , 2007, Cancer genetics and cytogenetics.
[20] M. Lacouture,et al. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib , 2007, Photodermatology, photoimmunology & photomedicine.
[21] G. Giaccone,et al. Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study , 2006, Clinical Cancer Research.
[22] F. Cappuzzo,et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] William Pao,et al. A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer , 2006, Cancer.
[24] A. Bezjak,et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Maemondo,et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Herbst,et al. Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways , 2006, Clinical Cancer Research.
[27] M. Meyerson,et al. Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.
[28] L. Paz-Ares,et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Dowlati,et al. Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Ladanyi,et al. EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Govindan,et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Hidalgo,et al. Final results of ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) , 2006 .
[33] F. Hirsch,et al. Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy , 2006, Clinical Cancer Research.
[34] J. Minna,et al. Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features , 2006, Clinical Cancer Research.
[35] Susan Journagan,et al. An acneiform eruption due to erlotinib: prognostic implications and management. , 2006, Journal of the American Academy of Dermatology.
[36] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[37] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[40] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[41] D. Gandara,et al. Intermittent erlotinib in combination with docetaxel (DOC): Phase I schedules designed to achieve pharmacodynamic separation , 2005 .
[42] P. Jänne,et al. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[44] Edward S. Kim,et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Rigas,et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] J. Pignon,et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. , 2004, JAMA.
[48] E. Van Cutsem,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[49] Christopher U. Jones,et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[51] Roy S Herbst,et al. Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.
[52] Daniel Jones. Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.
[53] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Sang-We Kim,et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. , 2003, Acta dermato-venereologica.
[57] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[58] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] M. Kuwano,et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. , 2002, Cancer research.
[61] F. Hirsch,et al. Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.
[62] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[63] G. Tortora,et al. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[64] E K Rowinsky,et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] M. Eichelbaum,et al. CYP3A genetics in drug metabolism , 2001, Nature Medicine.
[66] M. Kris,et al. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .
[67] J. Dancey,et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] R. Bjerkvig,et al. Effects of EGF, BFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain‐tumour biopsies In Vitro , 1993, International journal of cancer.
[69] J. Mendelsohn,et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. , 1984, The Journal of biological chemistry.
[70] Alona Muzikansky,et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. , 2007, The oncologist.
[71] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[72] P. Tsichlis,et al. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. , 1999, Annual review of biochemistry.
[73] W. Pryor. Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .